Publications by authors named "Marc Raab"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

117

Total Likes

80

Extended Reach

242,786

Social Features

43
S
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma.
Martin Grözinger, Muriel Schlanke, Jana Gröne, Stella Erdmann, Marina Hajiyianni, Marc S Raab

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma.
Joseph Kauer, Niels Weinhold, Marc S Raab

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.
Tim Richardson, Elias Mai, Ekaterina Menis, Axel Benner, Diana Tichy, Marc Raab

Eur J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Marc S Raab

Hemasphere· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.
Maximilian Merz, Nico Gagelmann, Samih Smaili, Sarah Flossdorf, Sandra Sauer, Marc S Raab

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.
Christos Sachpekidis, Marina Hajiyianni, Martin Grözinger, Maja Piller, Annette Kopp-Schneider, Marc S Raab

Eur J Nucl Med Mol Imaging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.
Niccolò Bolli, Mattia D'Agostino, Tina Bagratuni, Mario Boccadoro, Michele Cavo, Marc S Raab

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective systematic classification of causes of death in the course of multiple myeloma.
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, Mathias Hänel, Roland Fenk, Marc S Raab

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies.
Benjamin Diamond, Dhanvantri Chahar, Michael D Jain, Alexandra M Poos, Michael A Durante, Marc S Raab

Blood Cancer Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
Benjamin Diamond, Linda Baughn, Mansour Poorebrahim, Alexandra M Poos, Holly Lee, Marc S Raab

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Philippe Moreau, María-Victoria Mateos, Marc S Raab

Nat Rev Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal genomic dynamics shape clinical trajectory in multiple myeloma.
Francesco Maura, Marcella Kaddoura, Alexandra M Poos, Linda B Baughn, Bachisio Ziccheddu, Marc S Raab

Nat Genet· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma.
Jan H Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Marc S Raab

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, Jill Corre, Mattia D'Agostino, Marc S Raab

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, Jill Corre, Mattia D'Agostino, Marc S Raab

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network.
Niels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Marc S Raab

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [F]FDG PET/CT predicts survival in multiple myeloma.
Christos Sachpekidis, Olof Enqvist, Johannes Ulén, Annette Kopp-Schneider, Leyun Pan, Marc S Raab

Eur J Nucl Med Mol Imaging· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease.
Hanns-Martin Lorenz, Wolfgang Merkt, Juliane Brandt, Thomas Giese, Tarik Exner, Marc S Raab

Ann Rheum Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement.
Tobias Dittrich, Timon Hansen, Christoph R Kimmich, Kaya Veelken, Anna Jauch, Marc S Raab

Am J Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
Marc S Raab, Yael C Cohen, Fredrik Schjesvold, Kimberly Aardalen, Adwait Oka

Leukemia· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).
Floris Chabrun, Daniel Schwartz, Susanna Gentile, Elias Mai, Tulika Gupta, Marc Raab

Res Sq· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When the silence speaks: T-cell dysfunction in myeloma.
Mirco J Friedrich, Marc S Raab

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.
Jan H Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Marc S Raab

Hemasphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma.
Raphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, Lukas John, Johanna Wagner, Marc S Raab

Sci Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis